ANI PHARMACEUTICALS, INC Business Combination, Contingent Consideration, Liability, Current
ANI PHARMACEUTICALS, INC (ANIP) had Business Combination, Contingent Consideration, Liability, Current of $167.00 thousand as of 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent · last filed 2026-02-27
- 2025-12-31: Business Combination, Contingent Consideration, Liability, Current $167.00K.
- 2025-09-30: Business Combination, Contingent Consideration, Liability, Current $63.00K.
- 2025-06-30: Business Combination, Contingent Consideration, Liability, Current $483.00K.
- 2025-03-31: Business Combination, Contingent Consideration, Liability, Current $229.00K.
| Period end | Business Combination, Contingent Consideration, Liability, Current |
|---|---|
| 2025-12-31 | $167.00K 10-K · filed 2026-02-27 |
| 2025-09-30 | $63.00K 10-Q · filed 2025-11-07 |
| 2025-06-30 | $483.00K 10-Q · filed 2025-08-08 |
| 2025-03-31 | $229.00K 10-Q · filed 2025-05-09 |
| 2024-12-31 | $29.00K 10-K · filed 2026-02-27 |
| 2024-09-30 | $1.28M 10-Q · filed 2024-11-08 |
| 2024-06-30 | $841.00K 10-Q · filed 2024-08-06 |
| 2024-03-31 | $414.00K 10-Q · filed 2024-05-10 |
| 2023-12-31 | $12.27M 10-K · filed 2025-02-28 |
| 2023-09-30 | $23.94M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $25.02M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $22.76M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $0.00 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |